` CSCI (COSCIENS Biopharma Inc) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

CSCI
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, CSCI has underperformed S&P TSX Composite Index (Canada), delivering a return of -50% compared to the S&P TSX Composite Index (Canada)'s +21% growth.

Stocks Performance
CSCI vs S&P TSX Composite Index (Canada)

Loading
CSCI
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com

Performance Gap
CSCI vs S&P TSX Composite Index (Canada)

Loading
CSCI
S&P TSX Composite Index (Canada)
Difference
www.alphaspread.com

Performance By Year
CSCI vs S&P TSX Composite Index (Canada)

Loading
CSCI
S&P TSX Composite Index (Canada)
Add Stock

Competitors Performance
COSCIENS Biopharma Inc vs Peers

S&P TSX Composite Index (Canada)
CSCI
ABBV
AMGN
GILD
VRTX
Add Stock

COSCIENS Biopharma Inc
Glance View

Market Cap
12.4m CAD
Industry
Biotechnology

COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

CSCI Intrinsic Value
7.83 CAD
Undervaluation 50%
Intrinsic Value
Price
Back to Top